The Inhalation Therapy Nebulizer Market was worth around USD 1,969.4 million in 2021 and is estimated to grow to about USD 3,039.3 million by 2028, with a compound annual growth rate (CAGR) of approximately 7.5 percent over the forecast period.
The Inhalation Therapy Nebulizer Market was worth around USD 1,969.4 million in 2021 and is estimated to grow to about USD 3,039.3 million by 2028, with a compound annual growth rate (CAGR) of approximately 7.5 percent over the forecast period. The report analyzes the Inhalation Therapy Nebulizer Market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Inhalation Therapy Nebulizer Market.
Inhalation Therapy Nebulizer Market: Overview
A nebulizer is a drug delivery device that allows the medication to be administered into the lungs as a mist. These devices circulate pressured air through the liquid to create a thin mist that is inhaled through a mouthpiece or mask. The rising global incidence of respiratory illnesses, as well as the growing elderly population, are expected to drive market expansion throughout the forecast period. In addition, rising demand for new respiratory medication delivery devices, as well as their rapid adoption among the patient population, are expected to drive their utilization over the forecast period. The growing popularity of pneumatic nebulizers due to their ease of use and effectiveness is likely to have a favorable impact on growth. Furthermore, patients' need for new technologies with higher quality, smaller size, lighter weight, and convenience of use is driving greater adoption. As a result, increased demand for these devices is driving the industry ahead.
Currently, the global COVID-19 pandemic epidemic has increased demand for devices that can effectively prevent the spread of this respiratory infection. As the number of coronavirus cases rises, many countries are facing a major scarcity of ventilators and meter dosage inhalers. For the treatment of their respiratory disorders, many of the patients use a home nebulizer. If a patient with COVID-19 or suspected COVID-19 is using a nebulizer at home, it is critical. COVID-19 inhalation therapy is quite successful in fighting the virus. These factors will drive market expansion during the pandemic period. Many pharmaceutical companies are concentrating on creating effective treatments for Covid- 19 infections, which will primarily be administered by nebulizers. Positive responses from the clinical study are expected to drive market expansion. Furthermore, if medical device makers place a strong emphasis on the development of advanced equipment in this segment that limits the creation of aerosols, there is a greater likelihood of an increase in the growth of this market during the coronavirus pandemic.
Inhalation Therapy Nebulizer Market: Driver
The Increasing Incidence of Respiratory Disorders Will Drive Market Growth
Asthma, Chronic Obstructive Pulmonary Disease (COPD), and other respiratory disorders place a significant financial strain on the healthcare systems of many countries across the world. The prevalence of these illnesses has increased due to a variety of variables such as an increase in the smoking population, poor air quality, and so on. The frequency is constantly increasing in emerging countries, resulting in a high number of patients suffering from respiratory illnesses. Various government initiatives promoting early diagnosis and treatment are resulting in an increase in the number of individuals receiving treatment. This, combined with the rising entry of new goods onto the market, such as nebulization devices, has played a critical role in driving the use of these devices.
Inhalation Therapy Nebulizer Market: Restraint
The Presence of Alternative Treatment Options Limits Market Growth
This is a mature sector that is likely to experience competition as patients increasingly adopt replacement technology for treating respiratory problems. Healthcare practitioners are increasingly favoring inhalers, notably metered-dose inhalers, for asthma therapy. The clinical and operational benefits of MDIs in the treatment of asthma, as well as their reduced cost, have resulted in a rising migration of patients away from nebulization devices and toward inhalers. Furthermore, restrictive reimbursement policies in developing economies, as well as increased mesh costs, are expected to stymie the market during the forecast period.
Inhalation Therapy Nebulizer Market: Segmentation
The Inhalation Therapy Nebulizer Market is segregated based on Type, Application, and Distribution Channel.
By Type, the market is classified into Mesh Nebulizer, Pneumatic nebulizers, Ultrasonic Nebulizers, and Jet nebulizers. During the projected period, the Mesh Nebulizer segment is expected to increase at the quickest rate. Mesh nebulizers have long been the primary choice for producing novel nebulized pharmaceuticals. As a result, mesh nebulizers are expected to become more popular in the near future. This is due to their portability, convenience, and speed of therapy, as a result of their low residual volumes and precise lung administration. Thus, technological developments in mesh nebulizers, together with the creation of a new solution, are expected to fuel market expansion in the future.
By Distribution Channel, the market is classified into Hospital Pharmacy, Pharmacy Stores, and Others. During the projected period, hospital pharmacies are expected to dominate the inhalation treatment nebulizer market. This is mostly due to an increase in the number of patients suffering from illnesses that require treatment in hospitals with modern infrastructure and suitable amenities. Furthermore, the increasing number of hospitals, together with acceptable reimbursement rules, is helping to the expansion of this market.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
North America dominated the worldwide inhalation therapy nebulizer market in the forecast period. A higher prevalence of asthma and other chronic respiratory illnesses, as well as increased use of advanced portable ones in the region, have contributed to North America having a larger share of the global market. Asthma affects one out of every thirteen individuals in the United States, according to the Centers for Disease Control and Prevention (CDC). This equates to an estimated 25 million asthmatic persons in the United States. Furthermore, proper reimbursement rules in the region for these devices are projected to support market growth in the region.
The rising frequency of chronic respiratory disorders improved healthcare infrastructure, and an increasing number of medical device companies developing inhaled medication delivery devices to treat asthma and COPD are driving the Asia Pacific market. As the region's population leads a fast-paced lifestyle, patients seeking more portable nebulizer devices that may be readily transferred in times of need for patients suffering from asthma and other respiratory illnesses.
Some of the main competitors dominating the Inhalation Therapy Nebulizer Market include - Rossmax International Ltd., OMRON Corporation, Koninklijke Philips N.V., PARI Pharma, BD, Medline Industries, Inc., Briggs Healthcare, GF Health Products, Inc., Vectura Group plc, Beurer GmBH.
Global Inhalation Therapy Nebulizer Market is segmented as follows:
By Distribution Channel
Inhalation therapy is used for treating various diseases, such as asthma, COPD, etc. Inhalation therapy technique helps to restore or improve normal breathing function in patients with a variety of respiratory diseases and medical conditions. Inhalation therapy uses different inhaling agents to treat different respiratory diseases by administrating drugs via inhalation, targeting peripheral airways, lung tissue, airway secretion, etc. Today, inhalation therapy is the best choice for delivering drugs in the treatment of respiratory disorders, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Nebulizers are devices used to deliver medications in mist form for easy inhalation. Nebulizers convert drug solutions and suspensions into small aerosol droplets, which are inhaled through the mouthpiece of these devices.
As per the Global Asthma Network, about 339 million people suffer from asthma worldwide. Asthma reduces one’s quality of life and leads to premature death. Nearly 65 million people are affected with moderate to severe COPD, as per the World Health Organization (WHO) estimates. Globally, COPD caused about 5% of global deaths in 2005. The WHO estimates imply that COPD would become the third leading cause of death by 2030 unless immediate action is taken to control it.
Increasing prevalence of asthma, COPD, and other chronic respiratory diseases is driving this market’s growth. Other factors contributing to this market’s growth are rising environmental pollution, increasing geriatric population base susceptible to respiratory diseases, huge investments made in research and development for miniaturization of products for home use, and technological advancements in device manufacturing. Large amounts of drugs are required for nebulizer as there is drug loss during mist formation in the nebulizer device. Wastage of drug to be administered remains the main concern for nebulizer devices and might hamper the growth of this market. Use of inhalation therapy nebulizer for treating diabetes, migraine, and cancer might act as an opportunity for the players of inhalation therapy nebulizer market.
The inhalation therapy nebulizer market can be segmented based on product type, applications, end-user, and region. On the basis of product type, this market is categorized into the pneumatic nebulizer, ultrasonic nebulizer, and mesh nebulizer, which are based on the mechanism of mist formation. Inhalation therapy nebulizers have applications in various respiratory conditions and based on applications, this market is segmented into asthma, COPD, cystic fibrosis, and other applications. Asthma segment holds the maximum share in this market, whereas COPD is expected to grow at the highest CAGR during the forecast period. End-users for inhalation therapy nebulizer market are hospitals and clinics, home healthcare, and others.
The North American region will lead the market during the forecast period. Advanced technology and healthcare infrastructure, government initiatives to control asthma and COPD, and continuous research and development will fuel the growth of this market in North America. In the forecast period, Europe will be the second largest market, whereas Asia Pacific region will grow at the fastest rate. Healthcare investments and government initiatives to curb non-communicable diseases, like asthma and COPD, are some of the factors propelling the growth of the inhalation therapy nebulizer market in these regions. The Latin American market is anticipated to grow moderately during the forecast period. Substantial growth is expected in the Middle East and African region in the upcoming years.
Some key players of the inhalation therapy nebulizer market include Koninklijke Philips N.V., Omron Corporation, DeVilbiss Healthcare, PARI, Air Liquide Medical Systems, A&D Company, Limited, GF Health Products, Inc., Vyaire Medical Inc., 3M, 3A HEALTH CARE S.R.L., Trudell Medical International, and Allied Healthcare Products, Inc., among others.
The rising global incidence of respiratory illnesses, as well as the growing elderly population, are expected to drive market expansion throughout the forecast period. In addition, rising demand for new respiratory medication delivery devices, as well as their rapid adoption among the patient population, are expected to drive their utilization over the forecast period.
According to the Market Research report, the Inhalation Therapy Nebulizer Market was worth about 1,969.4 (USD million) in 2021 and is predicted to grow to around 3,039.3 (USD million) by 2028, with a compound annual growth rate (CAGR) of around 7.5 percent.
North America dominated the worldwide inhalation therapy nebulizer market in the forecast period. A higher prevalence of asthma and other chronic respiratory illnesses, as well as increased use of advanced portable ones in the region, have contributed to North America having a larger share of the global market.